RT @urotoday: #CALYPSO trial: Savolitinib and durvalumab in advanced papillary #RenalCancer. Francesca Jackson-Spence @BartsECMC joins @PBa….

RT @urotoday: #CALYPSO trial: Savolitinib and durvalumab in advanced papillary #RenalCancer. Francesca Jackson-Spence @BartsECMC joins @PBa….

Thank you to everyone who came and took part in our International Clinical Trials Day event! If you are interested in keeping up to date with our events, please send us message or email BartsECMC@qmul.ac.uk ✨ @ECMC_UK @NHSBartsHealth

Next up is Dr Usman Bashir @NHSBartsHealth talking all about Artificial Intelligence (AI) in cancer early diagnosis. A fascinating talk #InternationalClinicalTrialsDay #ICTD25 @ECMC_UK

Attendees at our @BartsECMC Patient event are currently listening to Prof @MarcoGerlinger @BartsGI_Cancer talking all about gastrointestinal cancers and ctDNA. Happening now in West Wing St Bart’s hospital @NHSBartsHealth @ECMC_UK

Our International Clinical Trials Day event is happening now! Organised by our @bartsecmc patient group. You are welcome to pop in to West Wing and listen to our speakers. Up first is @tompowles1 talking all about personalised cancer vaccines 💉🔬

Please come in person! Breakfast and lunch provided . Please sign up via Eventbrite . International Clinical Trial's Day

Join us for International Clinical Trials Day. Hear about latest cancer research success at Bart’s - new cancer blood tests, vaccines and new treatments . 📆 Thurs 22nd May 10am-2pm.📍 West Wing, St Bart’s hospital . Please sign up via link below . @Barts_Charity @ECMC_UK

RT @urotoday: #CALYPSO trial: Savolitinib and durvalumab in advanced papillary #RenalCancer. Francesca Jackson-Spence @BartsECMC joins @PBa….

RT @drfrankiejs: Watch my @urotoday interview summarising the papillary CALYPSO trial final survival data and ctDNA analysis. Originally pr….

Final survival data and ctDNA data from the CALYPSO trial presented by Dr Francesca Jackson-Spence at ASCO #GU25 - RR and OS are enhanced in MET-driven papillary RCC. ctDNA at baseline is prognostic. CtDNA may be a useful tool in papRCC @QMBCI @tompowles1 @urotoday @drfrankiejs

Dr Connor Wells presents interesting real world data from @BartsECMC showing how clinical trials matter! > 50% of our patients join kidney and bladder cancer trials where available at our centre @ASCO #GU25

Dr Francesca Jackson-Spence, PhD candidate at @BartsECMC presents final survival data and a novel ctDNA analysis from the @QMBCI led phase II CALYPSO trial at ASCO #GU25 looking at targeting MET in advanced papillary renal cancer @drfrankiejs.

Dr Elizabeth Nally @BethN01 from @BartsECMC presents at #GU25 .QoL tools and toxicity definitions require re-evaluation in the IO era. She validates novel tools within PRISM, a ph2 RCT. Response to Tx appears to influence QoL more than any other parameter, incl life changing tox

RT @DrChoueiri: Terrific work by @tompowles1 !! With >2 years of follow-up, 1L EV+P maintains superior OS and PFS vs chemo in la/mUC. cCR r….

Updated data from the transformative EV302 trial led by @tompowles1 presented at ASCO GU today reinforcing the EV+P combination as a new frontline standard of care for bladder cancer patients #GU25 @ASCO @Uromigos @TresUramigas

RT @DrChoueiri: Elegant presentation from @ResearchWyatt on the evolution of ctDNA detection and characterization! Session chaired by @Dana….

Great work from Professor Gerlinger and the GI team at Bart’s Experimental Cancer Medicine Centre ⭐️.

RT @QMBCI: @tompowles1 @QMULBartsTheLon @NHSBartsHealth @QMUL @CRUKCOLcentre Professor Fairley was a pioneer in the fields of chemotherapy….

RT @QMBCI: @tompowles1 @QMULBartsTheLon @NHSBartsHealth @QMUL @CRUKCOLcentre The medal commemorates the life of Gordon Hamilton Fairley, th….